Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$7.50 USD
+0.19 (2.60%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $7.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MYGN 7.50 +0.19(2.60%)
Will MYGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MYGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MYGN
Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?
MYGN Stock Might Gain on The Lancet Study Backing Precise MRD
MYGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain?
Compared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics
Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates
Other News for MYGN
Technical picture remains unchanged for MYGN after it rises 0.97% on September 15
MYGN forms Upper Bollinger Band Walk on September 12
Is MYGN primed for upward momentum? Expansion Breakout shows up after rallying 11.3%
MYGN Crosses Above Average Analyst Target
The technical outlook for MYGN is unchanged after it falls 1.0% on September 10